3 patents currently held
32 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Mar 2030. from the record
Of the 32 now held by other companies, 29 name Nagase Viita Co. Ltd. as their current owner, and 3 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Mar 2030
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Mar 2030 · Medium confidence
Also notable
Ends Feb 2043 · High confidence
Cellobiose 2-Epimerase, Its Preparation and Uses
US 9,175,282
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2030.
Sugar Composition Containing Cyclic Tetrasaccharide, Use Thereof, and Production Method Therefor
US 12,644,142
Granted 2026. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Jul 2029 · High confidence
The most cited patent in this portfolio, cited by 74 later US patents, top 10% of utility patents granted in 2012 in our data. Protection runs to 2029.
now held by Nagase Viita Co., Ltd.
Also notable
Ends Dec 2033 · High confidence
Cited by 44 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
now held by Nagase Viita Co., Ltd.
Also notable
Ends Dec 2031 · High confidence
The largest patent family in this portfolio, 6 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2031.
now held by Nagase Viita Co., Ltd.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 3, 2027The maintenance fee for Cellobiose 2-Epimerase, Its Preparation and Uses (US 9,175,282) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 1 term has ended since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Sugar Composition Containing Cyclic Tetrasaccharide, Use Thereof, and Production Method Therefor | 1 in force | to Feb 2043 |
| A Crystalline Potassium Salt of 2-O-ALPHA-D-GLUCOSYL-LASCORBIC Acid and Method for Producing the Same | 1 in force | to Feb 2042 |
| Cellobiose 2-Epimerase, Its Preparation and Uses | 1 in force | to Mar 2030 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,175,282 | Cellobiose 2-Epimerase, Its Preparation and Uses In force · Medium confidence | In force | Medium confidence | |
| US 12,338,264 | A Crystalline Potassium Salt of 2-O-ALPHA-D-GLUCOSYL-LASCORBIC Acid and Method for Producing the Same held by Nagase Viita Co., Ltd. In force · High confidence | In force | High confidence | |
| US 12,644,142 | Sugar Composition Containing Cyclic Tetrasaccharide, Use Thereof, and Production Method Therefor held by Nagase Viita Co., Ltd. In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 32 patents in force now held by others · 27 patents ended · 9 applications pending · 21 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed